Mounjaro (tirzepatide) and Wegovy (semaglutide) are genuinely transformative medications. The clinical trials show average weight losses of 15–22% of body weight — results that were previously only achievable with bariatric surgery. But buried in those impressive headline numbers is a fact that most prescribers do not emphasise enough: approximately 25–40% of the weight lost on GLP-1 medications is lean mass — muscle, bone-supporting tissue, and organ mass — not fat.
This matters enormously for long-term health, metabolic rate, physical function, and what happens when patients stop treatment. This article explains the mechanism, the risks, and exactly what you should be doing — both during and after GLP-1 treatment — to protect your body composition.
What Happens to Your Body on GLP-1 Medications
GLP-1 agonists work primarily by suppressing appetite, slowing gastric emptying, and improving insulin sensitivity. The dramatic caloric restriction they produce — most patients eat 30–50% fewer calories — is highly effective for fat loss but creates the same physiological challenge as any other significant caloric deficit: the body breaks down muscle tissue for energy alongside stored fat.
In clinical trials of semaglutide (STEP programme), roughly 40% of the weight lost was lean mass. Tirzepatide (SURMOUNT programme) showed slightly better fat-to-lean ratios but still significant lean mass loss. In absolute terms, a patient losing 20kg on Mounjaro might lose 8kg of muscle and bone-related tissue alongside 12kg of fat — a ratio that significantly undermines the health benefits of the treatment if not actively managed.
Bone density is a related but separate concern. Rapid weight loss of any kind — whether through dieting, surgery, or medication — is associated with reduced bone mineral density. This is compounded by the reduced mechanical loading on bones as bodyweight decreases, and by any reduction in dietary calcium and Vitamin D that accompanies reduced food intake.
Protecting Yourself During GLP-1 Treatment
1. Resistance Training — Non-Negotiable
The single most evidence-based intervention for preserving lean mass during caloric restriction is progressive resistance training. Resistance exercise sends a powerful anabolic signal to muscle tissue that overrides the catabolic pressure of a caloric deficit — essentially telling the body to preferentially burn fat rather than muscle.
The minimum effective dose is 2–3 sessions per week of compound resistance exercises (squats, deadlifts, rows, presses, or equivalent gym machine alternatives). The key word is progressive — you need to gradually increase load or volume over time to continue providing the stimulus needed to maintain muscle.
Walking and cardio alone are not sufficient. Cardio supports cardiovascular health and burns additional calories, but does not provide the mechanical load signal needed to preserve muscle.
2. Protein Intake — Higher Than You Think
Because GLP-1 medications dramatically reduce appetite, many patients eat far less protein than they need. Protein is the building block of muscle tissue and is essential for maintaining lean mass during weight loss. Current research in caloric restriction contexts suggests a target of 1.6–2.0g of protein per kilogram of target bodyweight per day — significantly higher than standard dietary guidelines.
For a patient targeting 75kg of bodyweight, this means 120–150g of protein daily. Achieving this on a significantly reduced appetite requires deliberate prioritisation of protein-dense foods: eggs, Greek yogurt, lean meat, fish, cottage cheese, or protein supplements.
3. Vitamin D and Calcium
With reduced food intake, supplementation of Vitamin D (at least 800–2000 IU daily) and calcium (500–1000mg daily if dietary intake is insufficient) is advisable throughout GLP-1 treatment. Vitamin D is also essential for muscle function independently of its bone health role — deficiency contributes directly to muscle weakness and fatigue.
4. Blood Tests — What to Monitor During Treatment
| Test | Why Monitor | Frequency |
|---|---|---|
| Full blood count | Detect anaemia from reduced nutrient intake | Every 3–6 months |
| Ferritin & iron studies | Iron deficiency is common with reduced meat intake | Every 3–6 months |
| Vitamin D | Assess need for supplementation | Every 6 months |
| B12 & folate | Reduced food volume risks deficiency | Every 6 months |
| Calcium & phosphate | Bone health markers | Every 6 months |
| Testosterone (men) | Significant caloric deficit suppresses testosterone production | Every 6 months |
| Thyroid (TSH) | Weight changes affect thyroid function; monitor if symptomatic | Annually or if symptomatic |
| HbA1c & fasting glucose | Monitor metabolic response to treatment | Every 3 months initially |
DEXA Scans — The Gold Standard for Body Composition
A DEXA (dual-energy X-ray absorptiometry) scan provides the most accurate available assessment of body composition — distinguishing fat mass, lean mass, and bone mineral density across different body regions. It is the only way to accurately know how much muscle vs fat you are losing during GLP-1 treatment.
We recommend a baseline DEXA scan before starting Mounjaro or Wegovy, and a follow-up scan after 6 months of treatment. This data allows your GP to assess whether your lean mass losses are within acceptable limits and whether specific interventions need to be intensified.
After Stopping Mounjaro or Wegovy
Whether you stop GLP-1 treatment by choice, because of side effects, or after reaching your target weight, the post-treatment period is the most critical window for protecting your results. Clinical data shows that most patients regain significant weight within 12 months of stopping without ongoing intervention. The key drivers are:
- Appetite returns to baseline — or often above baseline — as GLP-1 suppression is removed
- Reduced metabolic rate from muscle loss makes maintaining a caloric deficit harder
- Hormonal changes — particularly in men, where testosterone may have been suppressed during the caloric restriction period
Rebuilding Muscle After GLP-1 Treatment
The good news is that lost muscle can be rebuilt — but it requires a structured approach over 3–6 months:
- Increase calories strategically — a modest caloric surplus (200–300 calories above maintenance) combined with resistance training provides the energy and stimulus needed for muscle protein synthesis without triggering fat regain.
- Increase protein to 2.0–2.4g/kg of bodyweight — higher protein intake during the muscle-rebuilding phase maximises lean mass accrual.
- Progressive resistance training 3–4 sessions per week — increase intensity and volume gradually as strength returns.
- Check testosterone levels (men) — if testosterone was suppressed during treatment, it may not fully recover post-treatment and can be a significant barrier to muscle rebuilding. A private testosterone blood test at Lambert Medical will confirm whether this is a factor.
- Recheck Vitamin D and bone density markers — particularly if you lost >10% of body weight, a follow-up DEXA scan 6–12 months post-treatment provides important reassurance on bone health.
Hormonal Recovery in Men
This is an under-discussed aspect of post-GLP-1 recovery. Prolonged significant caloric restriction suppresses the hypothalamic-pituitary-gonadal axis in men, reducing testosterone production. Symptoms — fatigue, difficulty building muscle, low mood, reduced libido — can persist for months after stopping GLP-1 treatment even as weight stabilises.
A comprehensive hormone blood panel at Lambert Medical can identify whether testosterone levels have recovered or whether they warrant treatment. In some cases, a period of GP-supervised testosterone support is appropriate to facilitate the muscle-rebuilding phase. This is a clinical decision made on the basis of blood test results and symptoms — not a one-size-fits-all approach.